Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Alfa-2b Treatment to Increase Sustained Response in HBeAg-positive Chronic Hepatitis B (PEGON-study).
Phase of Trial: Phase IV
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Nucleosides; Nucleotides
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PEGON
- 17 Mar 2017 Primary endpoint (Sustained response) has not been met.
- 17 Mar 2017 Primary endpoint (Response at week 96) has not been met.
- 17 Mar 2017 Results assessing safety and efficacy of peginterferon in HBeAg-positive patients (n=77) and in the subgroup of interferon-naive patients (n=58), published in the Journal of Infectious Diseases